Spruce Biosciences, Inc.

NasdaqCM:SPRB Stock Report

Market Cap: US$18.1m

Spruce Biosciences Management

Management criteria checks 3/4

Spruce Biosciences' CEO is Javier Szwarcberg, appointed in Jan 2022, has a tenure of 2.92 years. total yearly compensation is $2.16M, comprised of 26.9% salary and 73.1% bonuses, including company stock and options. directly owns 1.13% of the company’s shares, worth $204.40K. The average tenure of the management team and the board of directors is 2.8 years and 4.8 years respectively.

Key information

Javier Szwarcberg

Chief executive officer

US$2.2m

Total compensation

CEO salary percentage26.9%
CEO tenure2.9yrs
CEO ownership1.1%
Management average tenure2.8yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

Insufficient Growth At Spruce Biosciences, Inc. (NASDAQ:SPRB) Hampers Share Price

May 29
Insufficient Growth At Spruce Biosciences, Inc. (NASDAQ:SPRB) Hampers Share Price

Is Spruce Biosciences, Inc. (NASDAQ:SPRB) Popular Amongst Institutions?

Jan 12
Is Spruce Biosciences, Inc. (NASDAQ:SPRB) Popular Amongst Institutions?

Spruce Biosciences outlines milestones for 2021

Jan 06

CEO Compensation Analysis

How has Javier Szwarcberg's remuneration changed compared to Spruce Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$39m

Jun 30 2024n/an/a

-US$43m

Mar 31 2024n/an/a

-US$47m

Dec 31 2023US$2mUS$580k

-US$48m

Sep 30 2023n/an/a

-US$49m

Jun 30 2023n/an/a

-US$48m

Mar 31 2023n/an/a

-US$47m

Dec 31 2022US$4mUS$540k

-US$46m

Compensation vs Market: Javier's total compensation ($USD2.16M) is above average for companies of similar size in the US market ($USD646.54K).

Compensation vs Earnings: Javier's compensation has been consistent with company performance over the past year.


CEO

Javier Szwarcberg (54 yo)

2.9yrs

Tenure

US$2,157,418

Compensation

Dr. Javier Szwarcberg, M.D., M.P.H., is CEO & Director of Spruce Biosciences, Inc. from January 2022. Dr. Szwarcberg is an accomplished physician executive with many years of leadership experience in the b...


Leadership Team

NamePositionTenureCompensationOwnership
Michael Grey
Executive Chairman7.7yrsUS$119.39k0%
$ 0
Javier Szwarcberg
CEO & Director2.9yrsUS$2.16m1.13%
$ 204.4k
Samir Gharib
President & CFO4.6yrsUS$1.20m0.85%
$ 153.4k
Ralph Charlton
Chief Medical Officer2.8yrsUS$1.00m0.39%
$ 70.6k
P. Ramtin
Senior Vice President of Business Operations2.3yrsno datano data
Heidi Petersen
Senior Vice President of Regulatory & Quality1.3yrsno datano data

2.8yrs

Average Tenure

54yo

Average Age

Experienced Management: SPRB's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Grey
Executive Chairman7.7yrsUS$119.39k0%
$ 0
Javier Szwarcberg
CEO & Director2.9yrsUS$2.16m1.13%
$ 204.4k
Daniel Spiegelman
Independent Director4.3yrsUS$106.89k0%
$ 0
Tiba Aynechi
Independent Director8.6yrsUS$99.39k0%
$ 0
Percival Barretto-Ko
Independent Director1.6yrsUS$127.84k0%
$ 0
Balaji Muralidhar
Independent Director4.8yrsUS$94.39k0%
$ 0
Camilla Simpson
Independent Director7.2yrsUS$98.39k0%
$ 0

4.8yrs

Average Tenure

53yo

Average Age

Experienced Board: SPRB's board of directors are considered experienced (4.8 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 17:37
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Spruce Biosciences, Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aydin HuseynovBenchmark Company
Martin AusterCredit Suisse
Raghuram SelvarajuH.C. Wainwright & Co.